The Problem
Cancer is a challenging therapeutic target. Cancer cells rapidly mutate, often metastasizing throughout the body. Because of these characteristics, therapies based on a single target or biological pathway typically have a limited efficacy window. For example, the twenty-seven (27) solid tumor cancer therapies approved by the FDA in the last five (5) years have a median survival extension of only 5.1 months. Meanwhile, the high toxicity of most cancer therapies typically results in a poor quality of life for patients.
Our Solution
NED’s combination therapies are designed to attack cancer on multiple fronts simultaneously. NED’s combinations utilize a dosing approach of the individual components at well-tolerated levels. We believe multi-component therapies will transform advanced cancer (stages II-IV) into a chronic, manageable disease.
We are developing NED-170, our lead therapeutic candidate, to be a first-in-class combination therapy. It is designed to simultaneously attack five key processes of all advanced solid tumor cancers using a well-tolerated, oral dosing regimen. We have observed the potential benefit and tolerability of the therapy in a cohort of observational patients. NED-170 holds promise not just to change long-term outcomes in numerous cancers, but to radically improve the patient experience during treatment.